Literature DB >> 17599727

The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.

Jean-Yves Reginster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17599727     DOI： 10.1002/art.22852

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  17 in total

1.  The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).

Authors:  O Bruyere; J A Kanis; M-E Ibar-Abadie; N Alsayed; M L Brandi; N Burlet; D L Cahall; A Chines; J-P Devogelaer; W Dere; N Goel; N Hughes; J-M Kaufman; S Korte; B H Mitlak; D Niese; R Rizzoli; L C Rovati; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-03-18       Impact factor: 4.507

2.  European regulatory perspectives for innovative therapies.

Authors:  S Ormarsdottir; J Y Reginster; E Abadie
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

3.  Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis.

Authors:  Jean-Hugues Salmon; Anne-Christine Rat; Isabelle Charlot-Lambrecht; Jean-Paul Eschard; Damien Jolly; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 4.  Type 2 diabetes mellitus and osteoarthritis.

Authors:  Nicola Veronese; Cyrus Cooper; Jean-Yves Reginster; Marc Hochberg; Jaime Branco; Olivier Bruyère; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Gabriel Herrero-Beaumont; Jean-François Kaux; Emmanuel Maheu; René Rizzoli; Roland Roth; Lucio C Rovati; Daniel Uebelhart; Mila Vlaskovska; André Scheen
Journal:  Semin Arthritis Rheum       Date:  2019-01-11       Impact factor: 5.532

Review 5.  Is Phytalgic(R) a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment.

Authors:  Robin Christensen; Henning Bliddal
Journal:  Arthritis Res Ther       Date:  2010-02-08       Impact factor: 5.156

Review 6.  Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis.

Authors:  Simon Wandel; Peter Jüni; Britta Tendal; Eveline Nüesch; Peter M Villiger; Nicky J Welton; Stephan Reichenbach; Sven Trelle
Journal:  BMJ       Date:  2010-09-16

7.  Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties.

Authors:  Lucio C Rovati; Federica Girolami; Stefano Persiani
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-06       Impact factor: 5.346

Review 8.  The role of ADAMTSs in arthritis.

Authors:  Edward A Lin; Chuan-Ju Liu
Journal:  Protein Cell       Date:  2010-02-07       Impact factor: 14.870

Review 9.  Role of glucosamine in the treatment for osteoarthritis.

Authors:  Jean-Yves Reginster; Audrey Neuprez; Marie-Paule Lecart; Nathalie Sarlet; Olivier Bruyere
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

10.  Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.

Authors:  Olivier Bruyère; Nansa Burlet; Pierre D Delmas; René Rizzoli; Cyrus Cooper; Jean-Yves Reginster
Journal:  BMC Musculoskelet Disord       Date:  2008-12-16       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.